BRAFV600E基因突变与甲状腺微小乳头状癌临床病理特征的相关性

Relationship between BRAFV600E gene mutation and clinicopathological features of papillary thyroid microcarcinoma

目的 探讨BRAF V600E 基因突变情况与甲状腺微小乳头状癌(papillary thyroid microcarcinoma,PTMC)临床病理特征的关系。方法 应用突变扩增阻滞系统(amplification refractory mutation system,ARMS)法检测173例PTMC的BRAFV 600E 基因突变情况,并分析其结果与PTMC患者的性别、年龄、肿瘤大小、病灶数、有无钙化、腺外浸润、淋巴结转移等临床病理特征的相关性关系。结果 173例PTMC患者中BRAF V600E 基因突变的突变率为60.12%(104/173),BRAF V600E 基因突变结果与肿瘤大小和淋巴结转移呈正相关(均 P <0.05),与患者的性别、年龄、病灶数、有无钙化和腺外浸润情况无关(均 P >0.05)。结论 BRAF V600E 基因突变可能与PTMC侵袭性生物学行为具有相关性,可为临床上手术方式的选择和患者预后判断提供一定参考价值。

Objective To investigate the relationship between BRAF V600E gene mutation and clinicopathological features of papillary thyroid microcarcinoma(PTMC). Methods The mutation of BRAF V600E gene in 173 patients with PTMC was detected by mutation refractory mutation system(ARMS). The correlations between the mutation and the clinicopathological characteristics of PTMC patients, such as gender, age, tumor size, number of lesions, calcification, extraglandular infiltration and lymph node metastasis, were analyzed. Results The mutation rate of BRAF V600E gene in PTMC was 60. 12%(104/173). The results of BRAF V600E gene mutation were positively correlated with tumor size and lymph node metastasis( P <0.05), but not correlated with gender, age, number of lesions, calcification and extraglandular infiltration( P >0.05). Conclusion Mutations of the BRAF V600E gene may be associated with invasive biological behaviors of PTMC, which may provide some reference for preoperative surgical selection and prognosis.